The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The aim of our study was to test whether the combined administration of the SSRI fluoxetine
and metformin, a drug improving metabolic profile and therefore potentially able to mimic the
influence of supportive living conditions on treatment outcome, results in an improved
antidepressant efficacy compared with fluoxetine alone.